PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin
Open Access
- 25 January 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 8 (1), 1-6
- https://doi.org/10.1038/s41598-018-19407-w
Abstract
Programmed cell death 1 ligand 1 (PD-L1) is a ligand of programmed cell death 1 (PD-1) that functions as an immune checkpoint by down-regulating immune responses. To determine whether PD-L1 is a therapy target in vitiligo treatment, Pmel-1 vitiligo mice were treated with a PD-L1 fusion protein. Treatment with this fusion protein significantly reversed/suppressed depigmentation development in adult Pmel-1 mice. Mechanistically, enrichment of regulatory T cells (Treg) in the skin was detected after PD-L1 fusion protein treatment in Pmel-1 mice. Furthermore, Tregs abundance was also increased in both the spleen and circulation of Pmel-1 mice treated with PD-L1. These data indicate that PD-L1 protein therapy inhibits the immune response and reverses depigmentation development in Pmel-1 vitiligo mice.This publication has 23 references indexed in Scilit:
- CCL22 to Activate Treg Migration and Suppress Depigmentation in VitiligoJournal of Investigative Dermatology, 2015
- Simvastatin Prevents and Reverses Depigmentation in a Mouse Model of VitiligoJournal of Investigative Dermatology, 2015
- B7 family checkpoint regulators in immune regulation and diseaseTrends in Immunology, 2013
- Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo PatientsJournal of Investigative Dermatology, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: Implications for the pathophysiology of vitiligoEuropean Journal of Cell Biology, 2004
- PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2001
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000
- Developmentally regulated expression of the PD-1 protein on the surface of double-negative(CD4–CD8–) thymocytesInternational Immunology, 1996
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996